BioVentrix Release: Updated "STICH" Study Concludes That Surgical Ventricular Reconstruction (SVR) in Conjunction with CABG Decreased Mortality by 64% in Heart Failure Patients Compared with CABG Procedure Alone at Four-Year Follow-up

Published: Jan 28, 2013

SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, an emerging medical device company, announced today that updated clinical data from the ‘STICH’ trial now in press and soon to be published in the Journal of Thoracic and Cardiovascular Surgery concludes: “In patients undergoing coronary artery bypass grafting (CABG) plus Surgical Ventricular Reconstruction (SVR), a survival benefit was realized compared with bypass alone in patients where the LV (Left Ventricle) volume was reduced below 70 mL/m2.”

Back to news